Home

CARB-X accelerates global antibacterial innovation by supporting the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our portfolio represents the world’s most scientifically diverse, early development pipeline of new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections.

361

$million

Invested

92

innovative

Projects

12

different

Countries

11

human clinical

TRIALS

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address drug-resistant bacterial infections.
Learn More


2020-2021

Annual Report

CARB-X closed its fifth fiscal year on July 31, 2021 with US$361 million awarded to 92 projects since inception

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Infectious Diseases Interventions, Wellcome Trust. Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

GHTC logo and Innovation award noticeProud recipient of the

2020 Innovating for Impact Partnership Award

from the Global Health Technologies Coalition (GHTC) 

Watch video

 

 

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Events

Events

06.09.22

 

ASM Microbe 2022

06.26.22

West Dover, VT

Gordon Research Conference: Bacterial Cell Surfaces

06.26.22

Smithfield, RI

Gordon Research Conference: Drug Resistance

CARB-X News

  • 11.19.2021  |  Partnering to Protect: Public & Private Sectors Unite Against Antimicrobial Resistance full release

  • 10.12.2021  |  CARB-X 2020-21 Annual Report: CARB-X surpasses all goals in first five years in combatting antibiotic resistant-bacteria full release

  • 07.29.2021  |  CARB-X celebrates five years of progress in early-stage product development against antibiotic-resistant bacteria full release

See All News

In The News

  • 05.12.2022  |  Are Antibiotics Doomed? David Hyun & Erin Duffy on the Crisis No One Talks About full story

  • 04.27.2022  |  ENTASIS THERAPEUTICS HOLDINGS INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) full story

  • 04.20.2022  |  SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001 full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.